Altura Energy Inc. Announces Grant of Stock Options
CALGARY, Alberta, Dec. 03, 2018 (GLOBE NEWSWIRE) — Altura Energy Inc. (“Altura” or the “Corporation”) (TSXV: ATU) announces that in […]
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects Observed corresponding trends […]
Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting
HOUSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense […]
TSX News -
OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
CG-806 Pan-FLT3/Pan-BTK Inhibitor Exhibits Favorable Safety Profile and Unexpected Potency on Primary Cells from B-cell Cancer Patients and AML Patients […]
Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019
— 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved […]
TSX News -
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
Data elucidate unique ability of CG-806 to overcome resistance to other FLT3 inhibitors in AML cells SAN DIEGO and TORONTO, […]
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today […]
Verisk to Acquire Rulebook
Combined power of Rulebook acquisition and Sequel enhances Verisk’s position as a leading provider of insurance software solutions to the […]
RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with […]
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
Potential Novel Target Discovery VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — Nash Pharmaceuticals Inc., a wholly owned subsidiary […]
